Competitive Dominance: Who Controls the Neurodegenerative Disease Market Share in the Era of Biogen and Eisai?
The competitive landscape of neurology has become a high-stakes chess match between a few global giants and a fleet of agile biotech disruptors. In 2026, the "Big Pharma" players are no longer trying to do everything themselves. Instead, they are acting as "platform companies," acquiring the most promising research from smaller firms. The battle for market share is fought not just in the...
0 Bình luận
0 Chia sẻ
947 Lượt xem